UBT37034 / United Laboratories - LARVOL DELTA

Phase I Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a Single Subcutaneous Injection of UBT37034 in Healthy Subjects and Overweight/Obese Subjects (ChiCTR) - P1 | N=42 | Sponsor: The Third Xiangya Hospital, Central South University; Xiangya Third Hospital of Central South University

New P1 trial • Genetic Disorders • Obesity

The clinical trial registration application for UBT37034 for injection for the indication of overweight or obesity received implicit approval for clinical trials from the China National Medical Products Administration on September 29, 2025, with acceptance number CXHL2500772. [Google translation] (Eastmoney.com)

New trial • Obesity

United Laboratories Announces UBT37034 Injection Approved by U.S. FDA for New Drug Clinical Trial [Google translation] (Sina Corp) - "United Pharmaceutical announced that the Class 1 innovative drug UBT37034 injection developed by the company's wholly-owned subsidiary United Biotech (Zhuhai Hengqin) Co., Ltd. has been approved by the U.S. Food and Drug Administration (FDA) with IND number 175188. The drug is suitable for overweight or obesity indications and is a new type of peptide receptor agonist that can reduce weight by selectively acting on the neuropeptide Y2 receptor."

IND • Obesity